Patient numbers up 1,300% in 5 yrs at Hyderabad drug treatment clinic
HYDERABAD: It's a high on a major leap. Fresh data tabled in Lok Sabha has thrown up a shocking 1300% jump in footfall over the last five years at Hyderabad's drug treatment clinic (DTC).
According to records submitted by the ministry of home affairs on July 22, the DTC at the city's Institute of Mental Health (IMH) saw the number of patients go up from 701 in 2020-21 to 9,832 in 2024-25 (up to Jan). It is the sharpest spike across all such major centres in India.
According to doctors at IMH, most patients visiting the clinic are addicted to alcohol, adulterated toddy and cannabis. The Hyderabad facility was set up in 2020.
"On an average, at least 30 patients come to the drug clinic every day. In a month, we easily record over 600 cases," said K Phanikanth, who heads the clinic at IMH. He added: "Recently, when the excise department conducted raids at toddy shops, there was an influx of patients with withdrawal symptoms. Our daily caseload went up to about 100."
Doctors and de-addiction experts attribute this astronomical rise to multiple factors - easy availability and affordability of drugs, increased anxiety and stress post pandemic and presence of a dedicated treatment facility that patients can go to.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Free P2,000 GCash eGift
UnionBank Credit Card
Apply Now
Undo
Stricter enforcement by the Anti-Narcotics Bureau making counselling mandatory under NDPS Act and growing awareness about substance abuse are also factors pushing the numbers up, they said.
"In fact, what this data indicates is just the tip of the iceberg," said K Devika Rani, a de-addiction expert. She added: "The problem of substance abuse is deeper. Thousands of people, especially youngsters, are hooked to drugs like cocaine, LSD, MDMA along with cannabis and alcohol.
The addiction is so severe that weaning them off is a near impossibility."
Set up with the All-India Institute of Medical Sciences (AIIMS), Delhi, as the nodal centre, DTCs run under govt-supported de-addiction programmes. They treat people, above the age of 18 and dealing with various addictions, as outpatients who are given anti-craving medication and psychological counselling.
While two DTCs, in Dibrugarh (Assam) and Agra (UP), saw a higher percentage rise in patient count compared to Hyderabad (1788% and 1400% respectively), absolute numbers in both these clinics were lower. While Assam's numbers went up from 25 in 2021-22 to 472 in 2024-25, in the case of Agra, it increased from 16 to 240 during the said period. Currently, India has 25 DTCs.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
18 hours ago
- News18
Cattle Virus Surges, Yet Goat Vaccine Used Despite India's Own Breakthrough Shot
Since 2022, India has a scientifically proven, indigenous Lumpy Skin Disease-specific vaccine readily available but there has been no national rollout despite outbreak warnings India is risking a severe wave of Lumpy Skin Disease (LSD) outbreaks among cattle by continuing to rely on an outdated vaccine despite having a scientifically proven shot, Dr Naveen Kumar, chief of the National Institute of Virology, Pune, has told News18. A painful and infectious viral disease, LSD, which primarily affects cattle and water buffalo, is resurging in parts of India, with fresh outbreaks reported in Maharashtra's Pune, Akola, Satara and Buldhana districts. However, the majority of Indian states, despite losing thousands of animals to LSD, are using 'goatpox vaccination' made from the goatpox virus (GTPV). The goatpox vaccine, as the name suggests, was originally developed for goats. It began to be used in cattle only as a temporary solution when no specific vaccine was available to protect them against the viral LSD. However, that is no longer the case. India, since 2022, has a scientifically proven, indigenous LSD-specific vaccine readily available. Kumar, who is director of India's premier virology institute and also the lead inventor of India's only LSD-specific vaccine, Lumpi-ProVac, told News18: 'While a safer and efficacious homologous vaccine is available, the country continues to use the goatpox vaccine." Kumar developed the vaccine during his stint at ICAR's National Research Centre on Equines (NRCE), Hisar, during the outbreak of the Covid-19 pandemic. In 2022, while Kumar and his team pushed for emergency approval of the vaccine, it wasn't able to get through, and India kept on using the goatpox vaccine. 'I isolated an LSD virus during the 2019 outbreak and developed a homologous, live-attenuated vaccine using the Ranchi strain. We developed Lumpi-ProVac, a homologous, live-attenuated vaccine, he said while adding that 'it remains India's only LSD-specific vaccine, offering 100 per cent protection with no adverse effects and far superior safety compared to global Neethling-based vaccines which are associated with adverse side effects such as local swelling, decrease in milk production and fever in up to 15 per cent vaccinated animals". He recalled the chronology of the making of the vaccine and added that following the controlled experimental trials in calves, the LSD vaccine was tested on more than 2.5 lakh animals in field trials. 'We have published data on 26,900 animals, proving that the vaccine is safe and effective. Otherwise, the requirement for such vaccine approval is testing on around 500-600 animals." However, he warned that with waning herd immunity from the 2022 wave, a larger outbreak is likely in 2025 if robust vaccination isn't ensured. Dual vaccine policy creating confusion Although the Department of Animal Husbandry and Dairying (DAHD) issued a letter on June 11, 2025, allowing the use of the LSD vaccine alongside goatpox, it stopped short of clearly discontinuing goatpox. As a result, most state animal husbandry departments continue prioritising goatpox, citing existing stockpiles and lack of directive. This has led to confusion among veterinary authorities and state policymakers. 'DAHD must issue clear instructions to phase out goatpox, as it offers limited protection. Moreover, simultaneous use of both vaccines raises the risk of recombination between the GTPV (Uttarkashi strain) and LSDV (Ranchi strain) vaccine viruses, potentially leading to the emergence of a more virulent virus," Kumar pointed out. Similar concern has been raised by the co-inventor of the vaccine, Dr BN Tripathi, who headed the National Research Centre on Equines (NRCE), Hisar, at the time Kumar invented the vaccine. 'This dual vaccine policy is causing deep confusion among state veterinary authorities," Tripathi, former deputy director general (Animal Science), Indian Council of Agricultural Research, Ministry of Agriculture and Farmers Welfare, told News18. 'Unless DAHD issues clear orders to phase out goatpox, states will keep using it, despite its poor protection. Worse, using both vaccines simultaneously could lead to recombination between the vaccine strains—potentially creating a more virulent virus." Despite vaccinating over 100 million cattle annually with goatpox since 2021, India has seen no conclusive evidence of its effectiveness. In Maharashtra alone, during the 2022 outbreak, over 4.18 lakh cattle contracted LSD despite being vaccinated, resulting in 32,000 deaths. 'Public spending on goatpox vaccine already exceeds Rs 400 crore annually," Tripathi said. Why are cattle being given a goat vaccine? According to veterinary animal scientist Tripathi, the misplaced strategy of using goatpox vaccine instead of Lumpi-ProVac could undo hard-won gains and trigger avoidable livestock losses. In March, Tripathi, who is now vice-chancellor, Sher-e-Kashmir University of Agricultural Sciences & Technology of Jammu, wrote a letter to the Secretary of the Department of Animal Husbandry, 'requesting the consideration for the adoption" of this vaccine. 'I am requesting your consideration for the adoption of this vaccine as soon as possible, given its approval by the Central Drug Standards Control Organisation (CDSCO). Despite this, a group of proponents of the goatpox vaccine has opposed the ICAR LSD vaccine without providing any scientifically valid arguments since its official release on August 10, 2022," wrote Tripathi, calling himself 'co-inventor" of the vaccine. Tripathi warns that unless mass immunisation with the homologous, live-attenuated vaccine is scaled up immediately, the country could see another devastating outbreak — especially during the monsoon, when hot and humid conditions heighten LSD transmission. While some officials credit the goatpox vaccine for the current decline in LSD cases, he points out the real reason is 'the temporary herd immunity conferred by the widespread 2022 outbreak". This outbreak killed 165,000 cattle and caused Rs 18,000 crore in economic losses. 'That immunity is now waning, and the goatpox vaccine lacks the immune strength to prevent a resurgence." Five firms have commercial licenses Following successful lab trials and large-scale field testing on 2.79 lakh cattle, including pregnant and lactating cows, the vaccine was licensed in 2022 for commercial production. The vaccine produced by Biovet, the Bharat Biotech group, was approved by the drug regulatory authority of India in October 2024, and the vaccine is commercially available with the trade name of 'Biolumpivaxin". There are five firms which are licensed to manufacture the vaccine, including Biovet, Hester Biosciences, Indian Immunologicals Ltd, IVBP Pune and a Karnataka government firm. 'It costs just Rs 1–2 per dose and has already demonstrated game-changing results in real-world deployments," Tripathi said. Unlike the goatpox vaccine, Lumpi-ProVac is the world's only DIVA (Differentiating Infected from Vaccinated Animals) marker vaccine, meeting the World Organisation of Animal Health (WOAH) standards. 'This gives India a critical edge for export and positions it to achieve freedom from infection status, which is impossible with goatpox," Tripathi highlighted. Hailed for 'Chamatkarik Parinam" by CM Yogi top videos View all The vaccine's transformative power was seen at Uttar Pradesh Chief Minister Yogi Adityanath's gaushala in Gorakhpur. Despite two rounds of goatpox vaccination, the LSD outbreak continued in 2023. At the CM's request, the indigenous vaccine was used — and the outbreak was brought under control almost immediately. 'He was informed that while the vaccine is not yet approved, this can be injected. The vaccine showed results and, in fact, at the Indian Veterinary Research Institute (IVRI) convocation on June 30, Yogi praised the vaccine's performance as a 'chamatkarik parinam" (miraculous outcome) and voiced frustration over delays in national rollout." About the Author Himani Chandna Himani Chandna, Associate Editor at CNN News18, specialises in healthcare and pharmaceuticals. With firsthand insights into India's COVID-19 battle, she brings a seasoned perspective. She is particularly More Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! view comments Location : New Delhi, India, India First Published: July 30, 2025, 10:21 IST News india Cattle Virus Surges, Yet Goat Vaccine Used Despite India's Own Breakthrough Shot Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
India Today
a day ago
- India Today
US health officials crack down on kratom products after industry complaints
US health officials are warning Americans about the risks of an opioid-related ingredient increasingly added to energy drinks, gummies and supplements sold at gas stations and convenience stores, recommending a nationwide chemical, known as 7- hydroxymitragynine, is a component of kratom, a plant native to Southeast Asia that has gained popularity in the US as an unapproved treatment for pain, anxiety and drug recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying it as a dangerously concentrated, synthetic form of the original ingredient. The FDA action 'is not focused on natural kratom leaf products," according to a statement Tuesday by the U.S. Department of Health and Human agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which includes LSD and heroin.'7-OH is an opioid that can be more potent than morphine," said FDA Commissioner Marty Makary. "We need regulation and public education to prevent another wave of the opioid epidemic.'The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances. A national ban wouldn't take effect until the agency drafts and finalizes new rules governing the regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with 7-OH. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and executives quickly applauded the FDA "demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary Tuesday, a rival group that supports the availability of 7-OH drugs criticized the government's move, pointing to the influence of kratom suppliers.'Big kratom trade groups have spent years blaming 7-OH for harms caused by their own unregulated products, because it threatens their market share,' the Holistic Alternative Recovery Trust stated in an emailed a decade ago, the federal government came close to banning 2016, the DEA announced plans to add it to the government's most restrictive schedule 1, reserved for drugs that have no medical use and a high potential for abuse. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine. Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level.- EndsMust Watch
Time of India
a day ago
- Time of India
Telemanas helpline in Telangana gets over one lakh calls since its launch in Oct 2022
Hyderabad: Since its launch in October 2022, the Tele-MANAS mental health helpline in Telangana has received more than 1.38 lakh calls from people seeking help for issues such as anxiety, depression, substance use, sleep problems, and suicidal thoughts. The 24/7 helpline, operating from the Institute of Mental Health (IMH) in Erragadda, is managed by a team that includes two psychiatrists, a clinical psychologist, 14 trained counsellors, and technical and support staff. The helpline offers free, confidential support through the toll-free number 14416. Kamareddy reported the highest number of calls at 19,366, followed by Hyderabad (9,904), Hanamkonda (8,086), Siddipet (7,911), and Vikarabad (7,067). The lowest number of calls were reported from Asifabad (1,144), Jayashankar Bhupalpally (1,359), Mulugu (1,562), Jagityal (1,742) and Nirmal (1,767) You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad Women comprised the majority of callers, with 92,013 reaching out for help compared to 45,911 men. The largest number of calls — 42,641 — came from individuals aged between 18 and 45. The centre receives around 150 to 200 calls daily, providing immediate support and referring serious cases to nearby district mental health programme (DMHP) clinics or govt hospitals.
